Yuhan and Johnson & Johnson Innovative Medicine (JJIM), formerly known as Janssen, ended a research project after securing ...

In the latest supply deal on the active pharmaceutical ingredients (API) front, Gilead Sciences has tapped South Korea’s ...

South Korean pharmaceutical giant Yuhan announced Friday it has terminated its collaboration with Janssen Biotech on the ...

Yuhan sealed a $80.9 million deal with California-based Gilead Sciences to supply pharmaceutical ingredients for the ...

Gilead Sciences, Inc. (Nasdaq: GILD) will present new data from the company’s broad lung cancer clinical development program during the IASLC 2024 World Conference on Lung Cancer hosted by the ...

On Wednesday, RBC Capital adjusted its outlook on Gilead Sciences (NASDAQ:GILD), increasing the price target to $74 from $72 while maintaining a Sector Perform rating. The revision follows ...

Here, Johanna Mercier, Chief Commercial Officer, shares how Gilead works to help remove barriers to care, improve health equity and increase access to life-changing therapies - all of which ...

Since my last article, Gilead Sciences, Inc.'s stock price has continued to rise, thanks in part to strong sales of its HIV portfolio and an improved EBIT margin year-over-year. So, sales of the ...

Gilead Sciences (NASDAQ:GILD) shares traded in the green on Tuesday, making it the seventh consecutive days of gains. The stock closed up 0.04% at $76.99. GILD stock fell about 0.06% in the last ...

Biotech giant Gilead Sciences, Inc. GILD has gained 16.8% in the past three months compared with the industry’s growth of 7.6%. The stock has also outperformed the sector and the S&P 500.

Yuhan's Lazcluze, licensed by Johnson & Johnson, has made history as the first Korea-developed novel cancer drug to be approved by the FDA. Merck has optioned in on one Kelun Biotech antibody-drug ...